An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort. Academic Article uri icon

Overview

abstract

  • Statins have been shown to induce a phosphoprotein signature that modifies MYC (myelocytomatosis viral oncogene) activation and to have anti-inflammatory activity that may impact the risk of Non-Hodgkin's lymphoma (NHL). We analyzed the relationship between statins and risk of NHL using data from the Women's Health Initiative (WHI). The study population included 161,563 postmenopausal women ages 50-79 years from which 712 cases of NHL were diagnosed after 10.8 years of follow-up. Information on statin use and other risk factors was collected by self- and interviewer-administered questionnaires. Multivariable-adjusted HR and 95% CI evaluating the relationship between statin use at baseline, as well as in a time-dependent manner and risk of NHL, were computed from Cox proportional hazards analyses. A separate analysis was performed for individual NHL subtypes: diffuse large B-Cell lymphoma (DLBCL) (n = 228), follicular lymphoma (n = 169), and small lymphocytic lymphoma (n = 74). All statistical tests were two-sided. There was no significant association between use of statins at baseline and risk of NHL (HR 0.85, 95% C.I. 0.67-1.08). However, in the multivariable-adjusted time-dependent models, statin use was associated with a borderline lower risk of NHL (HR 0.81, 95% C.I. 0.66-1.00). Considering subtypes of NHL, statin use was associated with a lower risk of DLBCL (HR 0.62, 95% C.I. 0.42-0.91). This effect was driven by lipophilic statins (HR 0.62, 95% C.I. 0.40-0.96). In the WHI, statins were associated with a lower overall risk of DLBCL, particularly attributable to lipophilic statins. These results may have impact on primary or secondary prevention of NHL, particularly DLBCL.

authors

  • Desai, Pinkal
  • Wallace, Robert
  • Anderson, Matthew L
  • Howard, Barbara V
  • Ray, Roberta
  • Wu, Chunyuan
  • Safford, Monika M
  • Martin, Lisa W
  • Schlecht, Nicolas
  • Liu, Simin
  • Cirillo, Dominic
  • Jay, Allison
  • Manson, JoAnn E
  • Simon, Michael S

publication date

  • April 2, 2018

Research

keywords

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Follicular
  • Lymphoma, Large B-Cell, Diffuse
  • Women's Health

Identity

PubMed Central ID

  • PMC5943473

Scopus Document Identifier

  • 85044740790

Digital Object Identifier (DOI)

  • 10.1002/cam4.1368

PubMed ID

  • 29608241

Additional Document Info

volume

  • 7

issue

  • 5